| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8076362 | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Jun, 2018
(5 years ago) | |
| US7750028 | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Oct, 2018
(5 years ago) | |
|
US8076362 (Pediatric) | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Dec, 2018
(5 years ago) | |
|
US7750028 (Pediatric) | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Apr, 2019
(5 years ago) | |
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(11 months ago) | |
Banzel is owned by Eisai Inc.
Banzel contains Rufinamide.
Banzel has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Banzel are:
- US8076362
- US7750028
- US8076362*PED
- US7750028*PED
- US6740669*PED
- US6740669
Banzel was authorised for market use on 14 November, 2008.
Banzel is available in suspension;oral, tablet;oral dosage forms.
Banzel can be used as treatment of epilepsy.
Drug patent challenges can be filed against Banzel from 15 May, 2015.
The generics of Banzel are possible to be released after 14 May, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | May 14, 2016 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 14, 2015 |
Drugs and Companies using RUFINAMIDE ingredient
NCE-1 date: 15 May, 2015
Market Authorisation Date: 14 November, 2008
Treatment: Treatment of epilepsy
Dosage: TABLET;ORAL; SUSPENSION;ORAL
BANZEL family patents
